| Theme | Gastroenteropancreatic Neuroendocrine Tumors | |
|---|---|---|
| Title | Non-functioning Pancreatic Neuroendocrine Tumor | |
| Publish Date | 2013/01 | |
| Author | Shuji Suzuki | Department of Surgery, Institute of Gastroenterology, Tokyo Womenʼ's Medical University |
| Author | Takashi Hatori | Department of Surgery, Institute of Gastroenterology, Tokyo Womenʼ's Medical University |
| Author | Akira Kimijima | Department of Surgery, Institute of Gastroenterology, Tokyo Womenʼ's Medical University |
| Author | Nana Oshima | Department of Surgery, Institute of Gastroenterology, Tokyo Womenʼ's Medical University |
| Author | Keiko Shiratori | Department of Internal Medicine, Institute of Gastroenterology, Tokyo Womenʼ's Medical University |
| Author | Masakazu Yamamoto | Department of Surgery, Institute of Gastroenterology, Tokyo Womenʼ's Medical University |
| [ Summary ] | Pancreatic neuroendocrine tumor (P-NET), which derive from the neuroendocrine cell system, are considered to be rare, constituting about 1-2 % of all pancreatic neoplasms. P-NET was classified into two groups of functioning PNETs with clinical symptoms and non-functioning P-NETs (NF-P-NET) without them. The frequency of NF-P-NET was 47.7 % out of all P-NETs. Patients with NF-P-NET generally displayed no symptoms, therefore they were diagnosed with imaging devises such as CTs, MRIs, ultrasonography or endoscopic ultrasonography (EUS). Cytological and pathological findings with EUS-FNA made it possible to produce final diagnoses. Medical treatment consisted of surgical resection, primarily, due to a lack of effective chemotherapy. P-NET metastases are often treated with reduction operations, along with intensive care provided by nonoperative methods and chemotherapy. | |